Scholarlink

Background <p>Photoimmunotherapy with ASP-1929 (cetuximab conjugated to IRDye 700DX) and 690-nm red light has shown promising results, with a 43% objective response rate (ORR) in a phase IIa trial for recurrent head and neck squamous cell carcinoma. This study aimed to evaluate the safety and efficacy of combining photoimmunotherapy with nivolumab for advanced gastric cancer.</p> Methods <p>This phase Ib open-label, single-center trial investigated the combination of photoimmunotherapy with ASP-1929 and nivolumab in patients with unresectable EGFR-positive gastric adenocarcinoma after standard chemotherapy. The dose-escalation part aimed to determine the recommended dose of laser illumination energy under endoscopy, and the expansion part assessed the safety and efficacy at the determined dose. The primary endpoint was dose-limiting toxicity (DLT), and treatment response and adverse events were evaluated.</p> Results <p>Between October 2019 and April 2022, 21 patients were enrolled. All patients had previously received at least two lines of chemotherapy, with six being refractory to anti-PD-1 therapy. No DLT was observed, and the recommended dose was 100&#xa0;J/cm<sup>2</sup>. Two patients achieved a partial response, and ORR was 9.5%.</p> Conclusion <p>This study demonstrated that combining endoscopic photoimmunotherapy with nivolumab is safe and feasible for advanced gastric cancer.</p> Trial registry <p>The trial is registered in the Japanese Registry of Clinical Trials (identifier: jRCT2080224884, <a href="https://jrct.niph.go.jp/en-latest-detail/jRCT2080224884">https://jrct.niph.go.jp/en-latest-detail/jRCT2080224884</a>)</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901)

  • 期刊论文

  • 发表日期：

    2025年5月15日

查看全文
  • Tomohiro Kadota,
  • Rika Fujii,
  • Shohei Koyama,
  • Daisuke Kotani,
  • Yusuke Yoda,
  • Miki Fukutani,
  • Mitsuko Suzuki,
  • Masashi Wakabayashi,
  • Takashi Ikeno,
  • Hironori Sunakawa,
  • Yoshiaki Nakamura,
  • Akihito Kawazoe,
  • Takuma Irie,
  • Nozomu Fuse,
  • Akihiro Sato,
  • Tomonori Yano,
  • Kohei Shitara

摘要

Background

Photoimmunotherapy with ASP-1929 (cetuximab conjugated to IRDye 700DX) and 690-nm red light has shown promising results, with a 43% objective response rate (ORR) in a phase IIa trial for recurrent head and neck squamous cell carcinoma. This study aimed to evaluate the safety and efficacy of combining photoimmunotherapy with nivolumab for advanced gastric cancer.

Methods

This phase Ib open-label, single-center trial investigated the combination of photoimmunotherapy with ASP-1929 and nivolumab in patients with unresectable EGFR-positive gastric adenocarcinoma after standard chemotherapy. The dose-escalation part aimed to determine the recommended dose of laser illumination energy under endoscopy, and the expansion part assessed the safety and efficacy at the determined dose. The primary endpoint was dose-limiting toxicity (DLT), and treatment response and adverse events were evaluated.

Results

Between October 2019 and April 2022, 21 patients were enrolled. All patients had previously received at least two lines of chemotherapy, with six being refractory to anti-PD-1 therapy. No DLT was observed, and the recommended dose was 100 J/cm2. Two patients achieved a partial response, and ORR was 9.5%.

Conclusion

This study demonstrated that combining endoscopic photoimmunotherapy with nivolumab is safe and feasible for advanced gastric cancer.

Trial registry

The trial is registered in the Japanese Registry of Clinical Trials (identifier: jRCT2080224884, https://jrct.niph.go.jp/en-latest-detail/jRCT2080224884)